CD4+ T and B cells cooperate in the immunoregulation of Experimental Autoimmune Myasthenia Gravis

Journal of Neuroimmunology

Volumn 179, Issue 1-2, 2006, Pages 152-162

  Milani, Monica ^a   Ostlie, Norma ^a   Wu, Huiyun ^a   Wang, Wei ^a   Conti Fine, Bianca M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Autoimmunity; B cells; CD4+ T cells; Th2 cytokines

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CYTOKINE; FREUND ADJUVANT; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL TRANSFER; CELLULAR IMMUNITY; COMPLEMENT FIXATION; CONTROLLED STUDY; CYTOKINE RELEASE; EXPERIMENTATION; FEMALE; IMMUNIZATION; IMMUNOREGULATION; MOUSE; MOUSE STRAIN; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; REDUCTION KINETICS; SYMPTOM; TH2 CELL; TORPEDO;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FREUND'S ADJUVANT; GENE EXPRESSION; GENE EXPRESSION PROFILING; IMMUNOGLOBULIN G; LYMPHOCYTE COOPERATION; MICE; MICE, INBRED C57BL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CHOLINERGIC; TORPEDO;

EID: 33748953709     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.07.004     Document Type: Article

References (39)

1. Abbas A.K., Murphy K.M., and Sher A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793
2. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., and Sarvetnick N. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186 (1997) 385-391
3. Bellone M., Ostlie N., Lei S.J., Wu X.D., and Conti-Tronconi B.M. The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J. Immunol. 147 (1991) 1484-1491
4. Berman P.W., and Patrick J. Experimental myasthenia gravis. A murine system. J. Exp. Med. 151 (1980) 204-223
5. Biesecker G., and Koffler D. Resistance to experimental autoimmune myasthenia gravis in genetically inbred rats. Association with decreased amounts of in situ acetylcholine receptor-antibody complexes. J. Immunol. 140 (1988) 3406-3410
6. Constant S.L., and Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15 (1997) 297-322
7. Conti-Fine B.M., Protti M., Bellone M., and Howard J.J.F. Myasthenia Gravis: The Immunobiology of an Autoimmune Disease (1997), R.G. Landes Company, Austin, TX
8. Deng C., Goluszko E., Tuzun E., Yang H., and Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169 (2002) 1077-1083
9. Fillatreau S., Sweenie C.H., McGeachy M.J., Gray D., and Anderton S.M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3 (2002) 944-950
10. Goluszko E., Deng C., Poussin M.A., and Christadoss P. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J. Neuroimmunol. 122 (2002) 85-93
11. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., and Gupta C.K. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 11 (1993) 293-306
12. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., M., L.N., Johnson L.L., Swain S.L., and Lund F.E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1 (2000) 475-482
13. Harrison L.C., and Hafler D.A. Antigen-specific therapy for autoimmune disease. Curr. Opin. Immunol. 12 (2000) 704-711
14. Heyman B. Feedback regulation by IgG antibodies. Immunol. Lett. 88 (2003) 157-161
15. Im S.H., Barchan D., Fuchs S., and Souroujon M.C. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J. Neuroimmunol. 111 (2000) 161-168
16. Im S.H., Barchan D., Maiti P.K., Raveh L., Souroujon M.C., and Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15 (2001) 2140-2148
17. Jouvin-Marche E., Morgado M.G., Leguern C., Voegtle D., Bonhomme F., and Cazenave P.A. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics 29 (1989) 92-97
18. Karachunski P.I., Ostlie N.S., Okita D.K., and Conti-Fine B.M. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100 (1997) 3027-3035
19. Karachunski P.I., Ostlie N.S., Okita D.K., and Conti-Fine B.M. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. J. Neuroimmunol. 95 (1999) 73-84
20. Karachunski P.I., Ostlie N.S., Monfardini C., and Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164 (2000) 5236-5244
21. Lennon V.A., Seybold M.E., Lindstrom J.M., Cochrane C., and Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147 (1978) 973-983
22. Lindblad E.S., and Spärck J.V. Basic concepts in the application of immunological adjuvant. Scand. J. Lab. Anim. Sci. 14 (1987) 1-13
23. Lindstrom J., Einarson B., and Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74 Pt C (1981) 432-460
24. Lund F.E., Garvy B.A., Randall T.D., and Harris D.P. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr. Dir. Autoimmun. 8 (2005) 25-54
25. Martin R.M., Silva A., and Lew A.M. The Igh-1 sequence of the non-obese diabetic (NOD) mouse assigns it to the IgG2c isotype. Immunogenetics 46 (1997) 167-168
26. Mauri C., Gray D., Mushtaq N., and Londei M. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197 (2003) 489-501
27. Medgyesi G.A., Fust G., Gergely J., and Bazin H. Classes and subclasses of rat immunoglobulins: interaction with the complement system and with staphylococcal protein A. Immunochemistry 15 (1978) 125-129
28. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., and Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16 (2002) 219-230
29. Moiola L., Galbiati F., Martino G., Amadio S., Brambilla E., Comi G., Vincent A., Grimaldi L.M., and Adorini L. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28 (1998) 2487-2497
30. Monfardini C., Milani M., Ostlie N., Wang W., Karachunski P.I., Okita D.K., Lindstrom J., and Conti-Fine B.M. Adoptive protection from experimental myasthenia gravis with T cells from mice treated nasally with acetylcholine receptor epitopes. J. Neuroimmunol. 123 (2002) 123-134
31. Ostlie N., Milani M., Wang W., Okita D., and Conti-Fine B.M. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J. Immunol. 170 (2003) 604-612
32. Poussin M.A., Goluszko E., David C.S., Franco J.U., and Christadoss P. HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production. J. Autoimmun. 17 (2001) 175-180
33. Romagnani S. Th1/Th2 cells. Inflamm. Bowel Dis. 5 (1999) 285-294
34. Saoudi A., Bernard I., Hoedemaekers A., Cautain B., Martinez K., Druet P., De Baets M., and Guery J.C. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. J. Immunol. 162 (1999) 7189-7197
35. Seder R.A., and Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12 (1994) 635-673
36. Uhr J.W., and Moller G. Regulatory effect of antibody on the immune response. Adv. Immunol. 8 (1968) 81-127
37. Wallberg M., Wefer J., and Harris R.A. Vaccination with myelin oligodendrocyte glycoprotein adsorbed to alum effectively protects DBA/1 mice from experimental autoimmune encephalomyelitis. Eur. J. Immunol. 33 (2003) 1539-1547
38. Wang W., Ostlie N.S., Conti-Fine B.M., and Milani M. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells. J. Immunol. 172 (2004) 97-103
39. Zhang G.X., Xiao B.G., Bai X.F., van der Meide P.H., Orn A., and Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162 (1999) 3775-3781